Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma

Journal of Gastrointestinal Surgery

Volumn 13, Issue 8, 2009, Pages 1470-1479

  Murakami, Yoshiaki ^a   Uemura, Kenichiro ^a   Sudo, Takeshi ^a   Hayashidani, Yasuo ^a   Hashimoto, Yasushi ^a   Nakamura, Hiroaki ^a   Nakashima, Akira ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Gemcitabine; Hilar cholangiocarcinoma; Postoperative adjuvant chemotherapy; Prognostic factor; S 1

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DRUG ANTAGONISM; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INTRAHEPATIC BILE DUCT; JAPAN; LIVER RESECTION; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; POSTOPERATIVE CARE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70349423540     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-0900-0     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. doi:10.3322/CA.2007.0010.
2. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-473. doi:10.1097/00000658-199610000-00005.
3. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Ohge H et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol 2007;95:207-212. doi:10.1002/jso.20668.
4. Reding R, Buard JL, Lebeau G, Launois B. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey. Ann Surg 1991;213:236-241. doi:10.1097/00000658-199103000-00010.
5. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270-276.
6. Schoenthaler R, Phillips TL, Castro J, Efird JT, Better A, Way LW. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 1994;219:267-274. doi:10.1097/00000658-199403000-00006.
7. Guthrie CM, Haddock G, De Beaux AC, Garden OJ, Carter DC. Changing trends in the management of extrahepatic cholangiocarcinoma. Br J Surg 1993;80:1434-1439. doi:10.1002/bjs.1800801128.
8. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;230:663-671. doi:10.1097/00000658-199911000-00008.
9. Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg 2004;240:95-101. doi:10.1097/01.sla.0000129491.43855.6b.
10. Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003;238:720-727. doi:10.1097/01.sla.0000094437.68038.a3.
11. Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 2005;190:810-815. doi:10.1016/j.amjsurg.2005.07.025.
12. Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384-394. doi:10.1097/00000658-199604000-00007.
13. Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997;15:947-954.
14. Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999;230:808-819. doi:10.1097/00000658-199912000-00010.
15. Todoroki T, Kawamoto T, Koike N, Takahashi H, Yoshida S, Kashiwagi H et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 2000;87:306-313. doi:10.1046/j.1365-2168.2000.01343.x.
16. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517. doi:10.1097/00000658-200110000-00010.
17. Ramesh H, Kuruvilla K, Venugopal A, Lekha V, Jacob G. Surgery for hilar cholangiocarcinoma: feasibility and results of parenchyma-conserving liver resection. Dig Surg 2004;21:114-122. doi:10.1159/000077335.
18. Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart B et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 2004;139:514-525. doi:10.1001/archsurg.139.5.514.
19. Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005;241:693-702. doi:10.1097/01.sla.0000160701.38945.82.
20. Dinant S, Gerhards MF, Busch OR, Obertop H, Gouma DJ, van Gulik TM. The importance of complete excision of the caudate lobe in resection of hilar cholangiocarcinoma. HPB Oxf 2005;7:263-267.
21. Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006;244:230-239. doi:10.1097/01.sla.0000217639.10331.47.
22. Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 2007;31:1256-1263. doi:10.1007/s00268-007-9001-y.
23. Miyazaki M, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery 2007;141:581-588. doi:10.1016/j.surg.2006.09.016.
24. Seyama Y, Kubota K, Sano K, Noie T, Takayama T, Kosuge T et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 2003;238:73-83. doi:10.1097/00000658-200307000-00010.
25. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12:183-186. doi:10.1023/A:1008352123009.
26. Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002;87:702-724. doi:10.1038/sj.bjc.6600543.
27. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332-2338. doi:10.1200/JCO.2005.51.008.
28. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004;91:1769-1774. doi:10.1038/sj.bjc.6602208.
29. Murakami Y, Uemura K, Hayasidani Y, Sudo T, Hashimoto Y, Ohge H, et al. Indication for postoperative adjuvant therapy in biliary carcinoma based on analysis of recurrence and survival after surgical resection. Dig Dis Sci 2008; in press (Oct 31).
30. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975;140:170-178.
31. International Union Against Cancer (UICC). TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss, 2002.
32. Kawasaki S, Imamura H, Kobayashi A, Noike T, Miwa S, Miyagawa S. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg 2003;238:84-92. doi:10.1097/00000658-200307000-00011.
33. Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000;46:581-587. doi:10.1016/S0360-3016(99)00472-1.
34. Gerhards MF, van Gulik TM, González González D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003;27:173-179.
35. Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol 2007;33:202-207. doi:10.1016/j.ejso.2006.09.033.
36. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788-798. doi:10.1097/00000658-199506000-00017.
37. Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 2005;35:548-552. doi:10.1007/s00595-005-2989-4.
38. Kim S, Kim SW, Bang YJ, Heo DS, Ha SW. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002;54:414-419. doi:10.1016/S0360-3016(02)02952-8.
39. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H et al. Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-1695. doi:10.1002/cncr.10831.
40. Matsumoto K, Nagahara T, Okano J, Murawaki Y. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 2008;20:863-872.
41. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yáñez M, Gamargo C et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001;12:1403-1406. doi:10.1023/A:1012543223020.
42. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006;94:1575-1579.
43. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakagawa N et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg 2008;195:757-762. doi:10.1016/j.amjsurg.2007.04.018.
44. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-277. doi:10.1001/jama.297.3.267.
45. Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689-1700. doi:10.1002/cncr.11699.